Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MenACWY-TT · 1 trial · 1 indication
Serogroups included: Neisseria meningitidis serogroup A (MenA), Neisseria meningitidis serogroup C (MenC), Neisseria meningitidis serogroup W-135 (MenW-135) and Neisseria meningitidis serogroup Y (MenY). The rSBA titer levels greater than or equal to (\>=) 1:32 for initially seronegative participants and at least four-fold increase in rSBA titer levels for initially seropositive participants, 1 month after booster vaccination were defined as booster response to meningococcal antigens and reported in this outcome measure. Initially seronegative participants were defined as participants with pre-vaccination rSBA titer levels below 1:8 and initially seropositive participants were defined as participants with pre-vaccination rSBA titer \>=1:8. Data reported below is including both seropositive and seronegative participants.
| Arm | Type | Description |
|---|---|---|
| MenACWY-TT Booster | EXPERIMENTAL | 10 year booster dose of MenACWY |
| Name | Type | Description |
|---|---|---|
| MenACWY-TT | BIOLOGICAL | Single dose of MenACWY-TT given 10 years after first vaccine with either MenACWY-TT or Mencevax ACWY |
Inclusion Criteria: * Subjects who, in the opinion of the investigator, can and will comply, with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits). * Written informed consent obtained from the subject prior to performing any study specific procedure...
MenACWY-TT is an investigational vaccine being studied for the prevention of Meningococcal ACWY Disease, a bacterial infection caused by Neisseria meningitidis serogroups A, C, W, and Y. It is being developed by Pfizer, Inc. (PFE) and is currently in Phase 3 clinical development.
MenACWY-TT targets the bacterial pathogen Neisseria meningitidis, specifically serogroups A, C, W, and Y. The vaccine is designed to elicit an immune response against these four serogroups, which are common causes of meningococcal disease.
MenACWY-TT is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The vaccine is currently in Phase 3 clinical trials for the prevention of Meningococcal ACWY Disease.
MenACWY-TT is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. One Phase 3 trial has been completed, and the vaccine is being evaluated for its safety and immunogenicity as a booster dose.
MenACWY-TT has been studied in one completed Phase 3 clinical trial, identified as NCT03189745. This trial evaluated a booster dose of MenACWY-TT administered 10 years after initial vaccination in healthy adults aged 20 years and older in the Philippines. The trial enrolled 229 participants.
MenACWY-TT is the vaccine candidate being studied in clinical trials, and it is also known as Nimenrix. In the Phase 3 trial NCT03189745, the vaccine was referred to as MenACWY-TT (Nimenrix), indicating that these names refer to the same vaccine product.